{"id":2993,"date":"2017-01-09T20:25:52","date_gmt":"2017-01-10T01:25:52","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=2993"},"modified":"2025-09-20T19:15:35","modified_gmt":"2025-09-21T01:15:35","slug":"aradigm-lost-orbit-hayward-problem","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2017\/01\/09\/2993\/aradigm-lost-orbit-hayward-problem\/","title":{"rendered":"Aradigm Lost in ORBIT \u2013 Hayward, We Have a Problem"},"content":{"rendered":"

\"\"<\/a><\/p>\n

It is interesting to see how often a discussion of study results moves from microbiology to clinical significance to statistical analysis details. When an antibiotic is not evaluated on the basis of its antimicrobial activity but on its ability to change a clinically relevant measure (the \u201cfeel, function, survive\u201d mantra popularized by FDA\u2019s statistical advisor Tom Fleming), we run into one major difficulty: There is only a very indirect relationship between microbial eradication and clinical outcome.<\/p>\n

Statistics to the rescue: For non-life-threatening conditions, mortality is obviously not a good outcome measure of efficacy.\u00a0 Then \u201cfeeling better earlier\u201d becomes the all-important test criterium. It may not be a big deal on the outside but being symptom-free faster is desirable when you are a patient, trust me. It was sufficient for the approval of our HSV and influenza medications which\u2013 on average \u2013 result in 1 day faster resolution of symptoms.\u00a0 Hence, \u201cfeeling better\u201d, \u201cfunctioning better\u201d matters to patients and regulators alike.<\/p>\n

Several development projects have tried to prove that \u2018Antibiotic A\u2019 leads to faster symptom relief than \u2018Antibiotic B\u2019.\u00a0 They all failed to prove the point: while occasionally a benefit was seen, this could not be replicated in subsequent confirmatory trials (see trials on recurrence of exacerbations for COPD).

Pulmaquin is a mixture of liposomal and non-encapsulated ciprofloxacin<\/span><\/p>\n<\/div><\/p>\n

The Aradigm ORBIT trials are different: here inhalational ciprofloxacin is compared to placebo in an attempt to show that reduction in bacterial CFU count matters clinically. The primary efficacy endpoint chosen was \u201cmedian time to first exacerbation\u201d in patients with non-CF bronchiectasis. Clearly, it becomes of critical importance to define \u201cexacerbation\u201d, to understand how bacterial load correlates with \u201cexacerbation\u201d, and what triggers an \u201cexacerbation\u201d other than bacteria and the quantitative parameter called bacterial load. This all needs to further related to P. aeruginosa, as this was the key targeted organism. Not an easy task \u2013 something for trail blazers.<\/p>\n

From the results of similar trials, we can confidently state that inhalational ciprofloxacin will reduce bacterial density in sputum including P. aeruginosa. We also are fairly confident that the drug delivery to bronchiectatic spaces should be adequate, assuming aeration. We are less confident that the condition under study, i.e., BE, is sensitive to study drug effect and that recurrence time to next exacerbation is the best primary efficacy endpoint.<\/p>\n

Here the data so far:
\nIn Phase 2, ORBIT-2 showed a significant reduction in \u201cmedian days to first exacerbation\u201d.
\nIn Phase 3, ORBIT-3 clearly missed the significance threshold (p=0.8488), and ORBIT-4 just barely made it (p=0.0462). As complete reports from either Phase 3 trial are unavailable, we refrain from further analysis. The company\u2019s press release\u00a0[1]<\/a> makes the excellent point that using a different statistical methodology would have shown significance.\u00a0 Yes, sure. Where did we hear that argument last time?<\/p>\n

Good to see that Pulmaquin prolonged the time to exacerbation (by approx. 2-3 months) in some patients. However, unlike CF trials, pulmonary function did not improve in BE patients which may explain the unconvincing results. But let\u2019s not quibble about statistics: it is clear already now that the well-designed\u00a0[2]<\/a> ORBIT studies will improve our knowledge of of the natural history of BE in a highly significant manner!<\/p>\n

 <\/p>\n

Abbreviations:
\n<\/strong>CF \u00a0 cystic fibrosis
\nBE \u00a0 bronchiectasis<\/p>\n

References:
\n<\/strong>[1]<\/a> Aradigm Press Release Dec 1, 2016,\u00a0 http:\/\/files.shareholder.com\/downloads\/ARDM\/3585942206x0x919507\/2B7D67AE-6002-494D-9453-0AE73CB290F2\/ARDM_News_2016_12_1_General_Releases.pdf
\n[2]<\/a> A O\u2019Donnell.\u00a0 ATS Internat\u2019l Conference 2016, San Francisco, Poster #A1775<\/p>\n","protected":false},"excerpt":{"rendered":"

It is interesting to see how often a discussion of study results moves from microbiology to clinical significance to statistical analysis details. When an antibiotic is not evaluated on the basis of its antimicrobial activity but on its ability to change a clinically relevant measure (the \u201cfeel, function, survive\u201d mantra Continue reading Aradigm Lost in ORBIT \u2013 Hayward, We Have a Problem<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":2996,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":true,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[19,227,3,18],"tags":[1866,1271,403,892,1868,1408,891,1583,1886,1887,1847,1870,1869,197,1840,1371],"class_list":["post-2993","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-qidp_antibiotic","category-recent_literature","category-the_news","category-the_viewpoint","tag-aerosolized-antibiotics","tag-allphase-pharma-consulting","tag-antibiotic-blog","tag-bronchiectasis","tag-ciprofloxacin-inhaled","tag-copd","tag-cystic-fibrosis","tag-harald-reinhart","tag-hsv-approval","tag-influenza-therapy","tag-nebulized-antibiotics","tag-non-cf-bronchiectasis","tag-orbit-trial","tag-p-aeruginosa","tag-pulmaquin","tag-qidp"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Aradigm-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-Mh","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":2205,"url":"https:\/\/allphasepharma.com\/dir\/2015\/12\/23\/2205\/qidp-antibiotics-2015-year-end-update\/","url_meta":{"origin":2993,"position":0},"title":"QIDP Antibiotics – 2015 Year-End Update","author":"Harald","date":"December 23, 2015","format":false,"excerpt":"Here an updated listing of all QIDP drugs we are aware of as of 12\/24\/2015. Today just\u00a0facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are\u00a058 drugs which garnered QIDP status and these are listed in the Main Table below. With the recent\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":2942,"url":"https:\/\/allphasepharma.com\/dir\/2016\/12\/15\/2942\/antibiotic-inhalers-galore-part-1-more-combinations-permutations-rubiks-cube\/","url_meta":{"origin":2993,"position":1},"title":"Antibiotic Inhalers Galore (Part 1): \u00a0More Combinations and Permutations than a Rubik\u2019s Cube","author":"Harald","date":"December 15, 2016","format":false,"excerpt":"There is much interest in inhaled antibiotics these days.\u00a0 Prima facie, the logic for this approach is compelling: Getting the antibiotic (and a lot of it) directly to the site of infection, while avoiding systemic toxicity, sounds like optimized efficacy plus optimized safety combined.\u00a0 However, some high-profile failures were published\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Inhalational-Abx-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Inhalational-Abx-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Inhalational-Abx-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1332,"url":"https:\/\/allphasepharma.com\/dir\/2015\/03\/28\/1332\/drugs-with-qidp-designation-update-3282015\/","url_meta":{"origin":2993,"position":2},"title":"Drugs with QIDP Designation \u2013 Update 4\/8\/2015","author":"Harald","date":"March 28, 2015","format":false,"excerpt":"For the latest QIDP listing, please click HERE Our latest internet search came up with 37 drugs that garnered QIDP status.\u00a0 They are listed in the Table below (if I missed a compound, please leave a comment!!). \u00a0The\u00a0table is searchable so you should be able to massage the data to\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"APPC + QIDP copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2817,"url":"https:\/\/allphasepharma.com\/dir\/2016\/10\/24\/2817\/qidp-drug-update-part-2-categories-of-interest\/","url_meta":{"origin":2993,"position":3},"title":"QIDP Drug Update \u2013 Part 2: \u00a0Categories of Interest","author":"Harald","date":"October 24, 2016","format":false,"excerpt":"According to Janet Woodcock, 63 drugs have been given the \u201cQIDP\u201d designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development.\u00a0 So we are in fairly close agreement. That may seem like an impressive record but it is also\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"qidp-part2-slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1314,"url":"https:\/\/allphasepharma.com\/dir\/2015\/03\/25\/1314\/aerosolized-antibiotics-selling-nebulizers\/","url_meta":{"origin":2993,"position":4},"title":"Aerosolized Antibiotics & Selling Nebulizers","author":"Harald","date":"March 25, 2015","format":false,"excerpt":"\u201cThe medicine comes for free, just pay us for the inhaler\u201d should be the marketing slogan for this group of therapeutics.\u00a0 Nebulizers are good business: hard to copy as a delivery system, they are a great opportunity to \u2018evergreen\u2019 off-patent antibiotics. The inhalational route to administer antibiotics is clearly attractive.\u00a0\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":2911,"url":"https:\/\/allphasepharma.com\/dir\/2016\/11\/25\/2911\/prospecting-antibiotics\/","url_meta":{"origin":2993,"position":5},"title":"Prospecting for New Antibiotics","author":"Harald","date":"November 25, 2016","format":false,"excerpt":"The QIDP designation was introduced in 2012 to incentivize drug development in antiinfectives. QIDP came with several attractive features, such as prolongation of patent life, FDA\u00a0expedited review and more.\u00a0 In addition, FDA made it quite easy to garner the label.\u00a0 As you can see, there is really no downside to\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"engine-qidp-blog","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=2993"}],"version-history":[{"count":5,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2993\/revisions"}],"predecessor-version":[{"id":3046,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2993\/revisions\/3046"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/2996"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=2993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=2993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=2993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}